BC Extra | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and RAPT managed to price NASDAQ IPOs within expectations ahead of Thursday’s session, and each posted gains in the...
BC Extra | Jul 9, 2019
Financial News

July 8 Financial Quick Takes: IGM raises mega-round; plus Mirium, Fulcrum set IPO ranges and more

IGM raises $102M C round IGM Biosciences Inc. (Mountain View, Calif.) raised $102 million in a series C round that included new investors Redmile Group, Janus Henderson Investors, Vivo Capital and an undisclosed U.S.-based healthcare...
BC Extra | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
BC Week In Review | Aug 18, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
BC Extra | Aug 17, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
BC Innovations | Aug 10, 2017
Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
BC Week In Review | Apr 12, 2017
Clinical News

BMS-986205: Ph I/IIa data

Data from 42 evaluable patients with advanced malignant tumors in an open-label, dose-escalation, international Phase I/IIa trial showed that once-daily 25-200 mg oral BMS-986205 for 2 weeks followed by BMS-986205 in combination with Opdivo nivolumab...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BC Extra | Aug 29, 2016
Financial News

Arcus discloses $119.7M in financings

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) emerged from stealth mode and disclosed it has raised $119.7 million raised in combined series A and B rounds. CEO Terry Rosen told BioCentury the company expects to move...
BioCentury | May 2, 2016
Finance

Pillars of strength

The Column Group plans to invest its biggest fund yet in fewer companies. The goal is to infuse enough capital into platform-based newcos that they can turn a blind eye to the capital markets. At...
Items per page:
1 - 10 of 24
BC Extra | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and RAPT managed to price NASDAQ IPOs within expectations ahead of Thursday’s session, and each posted gains in the...
BC Extra | Jul 9, 2019
Financial News

July 8 Financial Quick Takes: IGM raises mega-round; plus Mirium, Fulcrum set IPO ranges and more

IGM raises $102M C round IGM Biosciences Inc. (Mountain View, Calif.) raised $102 million in a series C round that included new investors Redmile Group, Janus Henderson Investors, Vivo Capital and an undisclosed U.S.-based healthcare...
BC Extra | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
BC Week In Review | Aug 18, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
BC Extra | Aug 17, 2017
Company News

Arcus gets rights to PD-1 mAb from WuXi, Gloria

WuXi Biologics Inc. (HKSE:2269) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) granted Arcus Biosciences (Hayward, Calif.) exclusive development and commercialization rights to PD-1 mAb GLS-010 (WBP3055). Arcus will gain rights in North America, Europe, Japan...
BC Innovations | Aug 10, 2017
Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
BC Week In Review | Apr 12, 2017
Clinical News

BMS-986205: Ph I/IIa data

Data from 42 evaluable patients with advanced malignant tumors in an open-label, dose-escalation, international Phase I/IIa trial showed that once-daily 25-200 mg oral BMS-986205 for 2 weeks followed by BMS-986205 in combination with Opdivo nivolumab...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BC Extra | Aug 29, 2016
Financial News

Arcus discloses $119.7M in financings

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) emerged from stealth mode and disclosed it has raised $119.7 million raised in combined series A and B rounds. CEO Terry Rosen told BioCentury the company expects to move...
BioCentury | May 2, 2016
Finance

Pillars of strength

The Column Group plans to invest its biggest fund yet in fewer companies. The goal is to infuse enough capital into platform-based newcos that they can turn a blind eye to the capital markets. At...
Items per page:
1 - 10 of 24